{
    "clinical_study": {
        "@rank": "77272", 
        "arm_group": [
            {
                "arm_group_label": "Control - Standard ART treatment", 
                "arm_group_type": "No Intervention"
            }, 
            {
                "arm_group_label": "Test - PGS", 
                "arm_group_type": "Experimental", 
                "description": "All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5,/6. Embryos will be vitrified. Patients will have a single hatching euploid blastocyst (*) replaced on a thawed cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "We propose to perform a clinical randomized trial to evaluate the effect of blastocyst\n      biopsy and whole chromosome analysis by Next Generation Sequencing (NGS) in comparison to\n      standard Assisted Reproductive Technologies (ART) methods on on implantation rates,\n      miscarriage rates, and pregnancy rates.\n\n      This will be three studies into one: a) a comparison of treatment (NGS) and no treatment, b)\n      a non-selection study based on the control group for which we will replace without knowing\n      the ploidy of the embryos, but we will know it later, c) a retrospective study about the use\n      of Mitochondrial DNA as a selection tool."
        }, 
        "brief_title": "Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis", 
        "condition": [
            "Infertility", 
            "Recurrent Pregnancy Loss"
        ], 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "detailed_description": {
            "textblock": "Patients following the inclusion criteria will be randomized into two groups:\n\n        1. Control group: All blastocyst embryos will be biopsied on day 5/6, but the biopsies\n           will be frozen and will not be analyzed before replacement. Blastocyst embryos will be\n           vitrified for future frozen embryo transfer (FET) cycle. Patients will have a single\n           hatching blastocyst (*) thawed and transferred into the uterus in a FET cycle based on\n           standard embryo quality assessment without NGS. After transfer, all biopsied samples\n           will be analyzed (the replaced embryo also, in order to do a non-selection study). If\n           patients in the control group do not have a pregnancy to term from that FET cycle,\n           euploid frozen blastocysts will be thawed and transferred on the next FET transfer.\n\n        2. Test group: All blastocyst embryos will be biopsied on day 5/6, and the biopsies will\n           be analyzed using NGS.  (*) and Biopsied blastocyst embryos will be vitrified for a\n           future frozen embryo transfer (FET) cycle. Patients will have a single hatching euploid\n           blastocyst (*) thawed and transferred into the uterus in a FET cycle\n\n      (*) Hatching blastocysts as described by Gardner and Schoolcraft (1999)\n\n      The Primary efficacy endpoint of comparing the study group with the control will be ongoing\n      implantation rate (# fetus reaching 2nd trimester / # embryos replaced).\n\n      All biopsied embryos from the test and control group will have their mitochondrial DNA\n      analyzed, but that information will not be used for purposes of choosing embryos for\n      replacement. Retrospectively but blindly (see blinding of results section), the information\n      will be used at the end of the study to determine which embryos have a higher chance of\n      implanting. If at that point the participating patients have remaining embryos frozen, they\n      will be able to use that information for purposes of embryo selection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients medically cleared to do a fresh or frozen embryo transfer.\n\n          -  Age up to 42 years\n\n        Exclusion Criteria:\n\n          -  microsurgical epididymal sperm aspiration (MESA) and Testicular sperm extraction\n             (TESE) patients\n\n          -  At least one partner carrier of a chromosomal or genetic disease\n\n          -  Abnormal ovarian reserve, defined as follicle stimulating hormone (FSH) of >10 IU/L\n             on day 2-4 of the cycle and anti-mullerian hormone (AMH) < 1ng /ml (If only one of\n             the two parameters altered then patients is acceptable). This is based on Mandy Katz\n             abstract at American Society for Reproductive Medicine (ASRM) 2011 where they showed\n             that these patients have 35% chance of having no euploid embryos - They are excluded\n             only to make the study size smaller, otherwise, if an euploid embryo is found in\n             these patients, they implant as well as patients with normal ovarian reserve. Not all\n             centers do AMH testing - we recommend first to run FSH and only test AMH if FSH is\n             abnormal.\n\n          -  Egg donor cycle (sperm donor is acceptable)\n\n          -  Gender selection cycles\n\n          -  Thaw cycles"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "42 Years", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946945", 
            "org_study_id": "Reprogenetics-3.109"
        }, 
        "intervention": {
            "arm_group_label": "Test - PGS", 
            "description": "PGD using blastocyst biopsy and testing of the biopsy by NGS", 
            "intervention_name": "Next Generation Sequencing after Blastocyst biopsy", 
            "intervention_type": "Genetic", 
            "other_name": "PGD: Preimplantation Genetic Diagnosis"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "infertility", 
            "recurrent pregnancy loss", 
            "miscarriage", 
            "Next Generation Sequencing"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "akung@reprogenetics.com", 
                "last_name": "Allen Kung, BSc", 
                "phone": "973-758-7970"
            }, 
            "facility": {
                "address": {
                    "city": "Livingston", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07039"
                }, 
                "name": "Reprogenetics"
            }, 
            "investigator": {
                "last_name": "Santiago Munne, Ph.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Standard ART Practice vs. Trophectoderm Biopsy, Whole Chromosome Analysis by Next Generation Sequencing, and Replacement of a Single Euploid Embryo", 
        "other_outcome": {
            "description": "The third aim of this study is to determine retrospectively if mt DNA content is linked to implantation potential and if that is measurable by NGS. NGS provides the additional advantage that it can measure mitochondrial DNA, which it's content, seems to be inversely correlated with implantation (Fragouli et al 2013, ASRM).", 
            "measure": "Correlation of Mitochondrial DNA and implantation", 
            "safety_issue": "No", 
            "time_frame": "When a fetal heartbeat is detected (8 weeks after implantation)"
        }, 
        "overall_official": {
            "affiliation": "Reprogenetics", 
            "last_name": "Santiago Munne, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We foresee a significant increase in ongoing implantation rates in the Test group compared to the Control group based on several studies showing about a 50% improvement of implantation rates after Preimplantation Genetic Diagnosis (PGD) with blastocyst biopsy and comprehensive chromosome analysis techniques The center participating in the study has an average 41.5% implantation rate of blastocysts in patients 35-39 years of age without PGD. Assuming that NGS will increase the detection power of chromosome abnormalities, we expect a higher implantation rate in the test group.\nFurthermore, we expect a 6% miscarriage rate in the Test group, based on extensive data from array comparitive genomic hybridization (aCGH) results (Hodes-Wertz et al. 2012), while about 21% in the Control group based on Society for Assisted Reproductive Technologies (SART) data (ages 35-40, SART 2011).", 
            "measure": "improvement in ongoing implantation rates", 
            "safety_issue": "No", 
            "time_frame": "When a fetal heartbeat is detected for each patient. (8 weeks after implantation)."
        }, 
        "reference": [
            {
                "PMID": "17141767", 
                "citation": "Cohen J, Wells D, Munn\u00e9 S. Removal of 2 cells from cleavage stage embryos is likely to reduce the efficacy of chromosomal tests that are used to enhance implantation rates. Fertil Steril. 2007 Mar;87(3):496-503. Epub 2006 Dec 4."
            }, 
            {
                "PMID": "19773223", 
                "citation": "De Vos A, Staessen C, De Rycke M, Verpoest W, Haentjens P, Devroey P, Liebaers I, Van de Velde H. Impact of cleavage-stage embryo biopsy in view of PGD on human blastocyst implantation: a prospective cohort of single embryo transfers. Hum Reprod. 2009 Dec;24(12):2988-96. Epub 2009 Sep 21."
            }, 
            {
                "PMID": "20971462", 
                "citation": "Guti\u00e9rrez-Mateo C, Colls P, S\u00e1nchez-Garc\u00eda J, Escudero T, Prates R, Ketterson K, Wells D, Munn\u00e9 S. Validation of microarray comparative genomic hybridization for comprehensive chromosome analysis of embryos. Fertil Steril. 2011 Mar 1;95(3):953-8. Epub 2010 Oct 25."
            }, 
            {
                "PMID": "19409550", 
                "citation": "Munn\u00e9 S, Wells D, Cohen J. Technology requirements for preimplantation genetic diagnosis to improve assisted reproduction outcomes. Fertil Steril. 2010 Jul;94(2):408-30. Epub 2009 May 5. Review."
            }, 
            {
                "PMID": "19939370", 
                "citation": "Schoolcraft WB, Fragouli E, Stevens J, Munne S, Katz-Jaffe MG, Wells D. Clinical application of comprehensive chromosomal screening at the blastocyst stage. Fertil Steril. 2010 Oct;94(5):1700-6. Epub 2009 Nov 25."
            }, 
            {
                "PMID": "3384119", 
                "citation": "Cohen J, DeVane GW, Elsner CW, Kort HI, Massey JB, Norbury SE. Cryopreserved zygotes and embryos and endocrinologic factors in the replacement cycle. Fertil Steril. 1988 Jul;50(1):61-7."
            }, 
            {
                "citation": "Forman EJ, Hong KH, Ferry KM, Tao X, Taylor D, Levy B, Treff NR, Scott RT (2013) In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial, Fertil Steril, in press (doi:10.1016/j.fertnstert.2013.02.056)"
            }, 
            {
                "citation": "Gardner DK and Schoolcraft WB. In vitro culture of human blastocysts. In: Jansen R, Mortimer D. eds. Towards Reproductive Certainty: Fertility and Genetics Beyond 1999. Carnforth, Parthenon Publishin, 1999, 378-88"
            }, 
            {
                "citation": "Scott RT, Ferry KM, Su J, Tao X, Scott K, Treff NR (2012) Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study. Fertil Steril, 2012, 97:870-875 (doi:10.1016/j.fertnstert.2012.01.104"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946945"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The pregnancy outcome of Controls patients with euploid embryos replaced will be compared to that of control patients with aneuploid embryos replaced. This will give us the specificity of the test (false positive rate) by obtaining the ongoing pregnancy rate of cycles with aneuploid embryos replaced, and the sensitivity of the test (false negative rate) by obtaining the miscarriage rate and ongoing pregnancy rate of cycles with euploid embryos replaced.", 
            "measure": "Determine specificity and sensitivity rates", 
            "safety_issue": "No", 
            "time_frame": "During a pregnancy term"
        }, 
        "source": "Reprogenetics", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Main Line Fertility Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Institute for Reproductive Medicine at Saint Barnabas Medical Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Reprogenetics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}